In Part 2 of the ASCO 2026 Highlights series, hosts Dr. Narjust Florez and Dr. Stephen Liu are joined by Dr. Julie Brahmer and Dr. Solange Peters to discuss some of the most notable immunotherapy advances presented at the 2026 ASCO Annual Meeting. The conversation explores emerging data for PD-1/VEGF and PD-L1/VEGF bispecific antibodies, the growing role of antibody-drug conjugates in combination with immunotherapy, and promising new strategies targeting KRAS-mutant lung cancers, highlighting how these approaches may reshape the future treatment landscape.Guests:Julie R. Brahmer, MD, MSc, FASCO, FAIOThe Marilyn Meyerhoff Professor of Thoracic OncologyCo-Leader, Cancer Immunology Research ProgramCo-Director, Upper Aerodigestive Cancers ProgramDirector, Johns Hopkins Kimmel Cancer Center, Bayview CampusProfessor Solange Peters, MD, PhDChair of Medical OncologyDirector of Oncology Department - CHUVLausanne University Hospital